Mark L. Baum
2016
In 2016, Mark L. Baum earned a total compensation of $3.2M as Chief Executive Officer at Imprimis Pharmaceuticals, a 3% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $153,043 |
|---|---|
| Option Awards | $544,860 |
| Salary | $372,386 |
| Stock Awards | $2,072,933 |
| Other | $10,600 |
| Total | $3,153,822 |
Baum received $2.1M in stock awards, accounting for 66% of the total pay in 2016.
Baum also received $153K in non-equity incentive plan, $544.9K in option awards, $372.4K in salary and $10.6K in other compensation.
Rankings
In 2016, Mark L. Baum's compensation ranked 2,989th out of 14,075 executives tracked by ExecPay. In other words, Baum earned more than 78.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,989 out of 14,075 | 79th |
Division Manufacturing | 1,033 out of 5,489 | 81st |
Major group Chemicals And Allied Products | 304 out of 1,895 | 84th |
Industry group Drugs | 221 out of 1,538 | 86th |
Industry Pharmaceutical Preparations | 171 out of 1,176 | 86th |
Source: SEC filing on April 27, 2017.
Baum's colleagues
We found two more compensation records of executives who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2016.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019